Cost analysis of an intravenous to subcutaneous epoetin α conversion

American Journal of Nephrology
Lori D WaznyMauro Verrelli

Abstract

A cost analysis of a conversion from intravenous (IV) to subcutaneous (SC) epoetin α in patients receiving chronic in-center hemodialysis (HD). This retrospective analysis compared epoetin α drug costs during a 6-month period of IV usage (July to December 2010, period 1) to a 6-month period of SC usage (July to December 2011, period 2) in four large in-center HD units. Data were collected from quarterly counts of HD patients receiving epoetin α and monthly inventory billing records. 622 HD patients who received IV epoetin α (period 1) were compared to 609 HD patients who received SC epoetin α (period 2). A 12.6% decrease in dose was observed. The average weekly cost of epoetin α was USD 173.02 per patient during the IV period versus USD 151.20 per patient during the SC period. This equated to a yearly cost savings of USD 1,135 per patient with SC epoetin α. The switch from IV to SC epoetin α was successfully implemented in all four centers and realized significant cost savings.

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
C A JohnsonM R Kosorok
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Francesco LocatelliAngel L Martín de Francisco
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Anatole BesarabJohn Hornberger
© 2021 Meta ULC. All rights reserved